Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.66 |
| ▸ | EGFR | P00533 | 5/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719422 | 0.87 | PIK3C3 (0.54) | PIK3CAPIK3CDPIK3CGPIK3CBNPC1 | |
| SCHEMBL3655267 | 0.85 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL3762546 | 0.84 | PIK3CD (0.69) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL3656586 | 0.83 | PIK3CA (0.83) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1543919 | 0.82 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL3662733 | 0.82 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL3758319 | 0.82 | PIK3CA (0.77) | PIK3CAPIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL1543840 | 0.82 | PIK3CA (0.77) | PIK3CAPIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL1543410 | 0.81 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGPIK3CBEGFR | |
| SCHEMBL3764342 | 0.81 | PIK3CA (0.71) | PIK3CAPIK3CDPIK3CGPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | claimed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | claimed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | PIK3CA 1/4885PIK3CD 5/4885PIK3CG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.